Aastrom Biosciences Reports First Quarter 2012 Financial Results
May 10, 2012 16:01 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 10, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Announces First Patient Enrolled in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T
May 09, 2012 17:12 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 9, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in Dilated Cardiomyopathy Patients at SCAI Scientific Sessions
May 07, 2012 16:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Webcast Alert: Aastrom to Host First Quarter 2012 Investor Call on May 10, 2012
May 07, 2012 16:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Hold Annual Meeting of Shareholders on May 3, 2012
April 30, 2012 16:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 30, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Final Results from RESTORE-CLI Phase 2b Clinical Trial for Ixmyelocel-T in Treatment of Critical Limb Ischemia Published in the Peer-Reviewed Journal Molecular Therapy
April 05, 2012 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom to Present at the Needham & Company 11th Annual Healthcare Conference
March 28, 2012 16:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 28, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present New Findings on Atheroprotective Effects of Ixmyelocel-T at Keystone Symposia on Atherosclerosis
March 26, 2012 09:15 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 26, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Appoints Dr. LaVonne Lang as Head of Regulatory Affairs
March 14, 2012 09:21 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 14, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Fourth Quarter and Year-End 2011 Financial Results
March 12, 2012 16:11 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., March 12, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...